Viral replacement or proportional change? Respiratory surveillance as RSV prevention expands in Latin America
Maternal immunisation with RSVpreF and infant immunisation with the long-acting monoclonal antibodies nirsevimab and clesrovimab are reshaping prevention of respiratory syncytial virus (RSV) disease. Trials showed that RSVpreF reduced severe RSV-associated lower respiratory tract illness and that both antibodies reduced RSV-associated hospitalisations in infants.1–3 As RSV disease declines, however, a larger share of remaining respiratory admissions may test positive for other viruses. Distinguishing that proportional change from a true increase in their incidence is an urgent surveillance question for Latin America.
Authors
- María Luisa Avila-Aguero (ORCID: https://orcid.org/0000-0002-1979-0431)
- Jose Manuel Brea (ORCID: https://orcid.org/0000-0002-5523-1979)
- Angela S. de Gentile (ORCID: https://orcid.org/0000-0002-1072-7700)
- Luiza Helena Falleiros-Arlant
- Xavier Sáez‐Llorens (ORCID: https://orcid.org/0000-0002-1149-5905)
Institutions
- Costa Rican Department of Social Security (CR)
- Instituto Tecnológico de Santo Domingo (DO)
- Yale University (US)
- CEVAXIN (PA)
- Secretaría Nacional de Ciencia, Tecnología e Innovación (PA)
- Hospital Nacional de Niños (CR)
- Universidade Metropolitana de Santos (BR)
- Hospital del Niño (PA)
- Hospital General de Niños Ricardo Gutierrez (AR)
Publication Details
- Journal
- The Lancet Regional Health - Americas
- Published
- 2026-10-30
- DOI
- https://doi.org/10.1016/j.lana.2026.101693
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00